Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Trial Profile

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tucatinib (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Lung cancer; Ovarian cancer; Prostate cancer; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics
  • Sponsors Seagen; Seattle Genetics
  • Most Recent Events

    • 04 Jan 2017 Results analysing maximum tolerated dose(MTD), pharmacokinetics and antitumor activity published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 07 Oct 2013 Final results will be presented at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research according to an Oncothyreon media release. Results were also reported in the media release.
    • 30 May 2013 Results reported in an Oncothyreon and Array BioPharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top